{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urologic+Neoplasms&page=7",
    "query": {
      "condition": "Urologic Neoplasms",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 2409,
    "total_pages": 241,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urologic+Neoplasms&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Urologic+Neoplasms&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-06T14:26:14.091Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00303732",
      "title": "Vatalanib and Everolimus in Treating Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "RAD001 (everolimus)",
          "type": "DRUG"
        },
        {
          "name": "PTK787 (vatalanib)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel George, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2004-12",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2016-03-03",
      "last_synced_at": "2026-10-06T14:26:14.091Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00303732"
    },
    {
      "nct_id": "NCT02762006",
      "title": "Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Cell Carcinoma",
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        },
        {
          "name": "Tremelimumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Moshe Ornstein",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2016-12-20",
      "completion_date": "2020-11-06",
      "has_results": false,
      "last_update_posted_date": "2024-03-18",
      "last_synced_at": "2026-10-06T14:26:14.091Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Cleveland, Ohio",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02762006"
    },
    {
      "nct_id": "NCT05649306",
      "title": "Gender Related Coping and Survivorship for Genitourinary Cancers",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Additional Education",
          "type": "OTHER"
        },
        {
          "name": "Questionnaires",
          "type": "OTHER"
        },
        {
          "name": "Attendance Diary",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 80,
      "start_date": "2023-01-20",
      "completion_date": "2029-09",
      "has_results": false,
      "last_update_posted_date": "2025-10-03",
      "last_synced_at": "2026-10-06T14:26:14.091Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Baltimore, Maryland",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05649306"
    },
    {
      "nct_id": "NCT00588276",
      "title": "Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cervical Cancer",
        "HEENT Cancer",
        "Renal Cancer",
        "Uterine Cancer",
        "CERVIX UTERI NOS",
        "RECTUM"
      ],
      "interventions": [
        {
          "name": "124I-Iodo-Azomycin Galacto-Pyranoside",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2005-06",
      "completion_date": "2012-06",
      "has_results": false,
      "last_update_posted_date": "2015-12-24",
      "last_synced_at": "2026-10-06T14:26:14.091Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00588276"
    },
    {
      "nct_id": "NCT07217171",
      "title": "A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Bladder Cancer",
        "Squamous Cell Carcinoma of the Lung",
        "Esophageal Squamous Cell Carcinoma",
        "Tongue Squamous Cell Carcinoma",
        "Cutaneous Squamous Cell Cancer",
        "Penile Squamous Cell Carcinoma",
        "Anal Squamous Cell Carcinoma",
        "Vulvar Squamous Cell Carcinoma",
        "Cervical Squamous Cell Carcinoma",
        "Vaginal Squamous Cell Carcinoma",
        "Urethral Squamous Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "EVOLVE104",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "EvolveImmune United, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2025-11-13",
      "completion_date": "2031-01-29",
      "has_results": false,
      "last_update_posted_date": "2026-09-15",
      "last_synced_at": "2026-10-06T14:26:14.091Z",
      "location_count": 16,
      "location_summary": "Duarte, California • Los Angeles, California • San Francisco, California + 10 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07217171"
    },
    {
      "nct_id": "NCT03165721",
      "title": "A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Paraganglioma",
        "Gastrointestinal Stromal Tumors",
        "Carcinoma, Renal Cell",
        "Renal Neoplasms",
        "Pheochromocytoma"
      ],
      "interventions": [
        {
          "name": "SGI-110 (guadecitabine)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "12 Years to 99 Years"
      },
      "enrollment_count": 9,
      "start_date": "2017-08-16",
      "completion_date": "2020-02-24",
      "has_results": true,
      "last_update_posted_date": "2026-02-18",
      "last_synced_at": "2026-10-06T14:26:14.091Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03165721"
    },
    {
      "nct_id": "NCT04774952",
      "title": "Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "RMC-5552",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Revolution Medicines, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 58,
      "start_date": "2021-04-07",
      "completion_date": "2024-06-28",
      "has_results": false,
      "last_update_posted_date": "2025-04-15",
      "last_synced_at": "2026-10-06T14:26:14.091Z",
      "location_count": 8,
      "location_summary": "Irvine, California • Sacramento, California • San Francisco, California + 5 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04774952"
    },
    {
      "nct_id": "NCT02145871",
      "title": "A Prospective Randomized Controlled Clinical Trial of Standard Versus Goal-Directed Perioperative Fluid Management (GDT) for Patients Undergoing Radical Cystectomy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "standard fluid management",
          "type": "OTHER"
        },
        {
          "name": "fluid management guided by the EV1000",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 282,
      "start_date": "2014-05-21",
      "completion_date": "2024-03-14",
      "has_results": false,
      "last_update_posted_date": "2024-03-20",
      "last_synced_at": "2026-10-06T14:26:14.091Z",
      "location_count": 5,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02145871"
    },
    {
      "nct_id": "NCT00011414",
      "title": "Phase I Trial of Tariquidar (XR9576) in Combination With Doxorubicin, Vinorelbine, or Docetaxel in Pediatric Patients With Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Wilms' Tumor",
        "Sarcoma",
        "Adenaocortical Carcinoma",
        "Refractory Cancer",
        "Coldrhood Cancer"
      ],
      "interventions": [
        {
          "name": "Tariquidar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "2 Years to 18 Years"
      },
      "enrollment_count": 29,
      "start_date": "2001-02-15",
      "completion_date": "2016-01-13",
      "has_results": false,
      "last_update_posted_date": "2019-07-16",
      "last_synced_at": "2026-10-06T14:26:14.091Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00011414"
    },
    {
      "nct_id": "NCT00458484",
      "title": "Radiosurgery in Treating Patients With Kidney Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "stereotactic radiosurgery",
          "type": "RADIATION"
        },
        {
          "name": "Renal Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Serum Blood Markers",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2007-02-20",
      "completion_date": "2019-09-12",
      "has_results": true,
      "last_update_posted_date": "2020-07-22",
      "last_synced_at": "2026-10-06T14:26:14.091Z",
      "location_count": 3,
      "location_summary": "Cleveland, Ohio • Orange, Ohio • Westlake, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Orange",
          "state": "Ohio"
        },
        {
          "city": "Westlake",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00458484"
    }
  ]
}